<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3034">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04424056</url>
  </required_header>
  <id_info>
    <org_study_id>2020-23</org_study_id>
    <nct_id>NCT04424056</nct_id>
  </id_info>
  <brief_title>A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease</brief_title>
  <acronym>INFLAMMACOV</acronym>
  <official_title>An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID19-associated disease may have different clinical aspects classified in 3 stages. Some&#xD;
      patients initially presenting with a non-hypoxemic viral pneumonia (stage 2a) may evolve&#xD;
      toward a more severe stage 2b or 3 (acute respiratory distress syndrome, ARDS) around the 7th&#xD;
      or 10th day of evolution, with a severe biological inflammatory syndrome (CRP&gt;200 mg/l), and&#xD;
      some times more severe complications such as acute renal insufficiency, consumptive&#xD;
      coagulopathy or shock, requiring increasing oxygen therapy, ICU admission, invasive&#xD;
      mechanical ventilation and possibly leading to death. This detrimental evolution is due to a&#xD;
      host-derived &quot;cytokine storm&quot; with a great excess of circulating inflammatory cytokines. In&#xD;
      animal models of ARDS complicating coronavirus or influenza virus infection, the cytokine&#xD;
      storm has been linked to hyperactivation of the NLRP3 inflammasome. NLRP3 constitutes an&#xD;
      intracellular protein platform which is responsible for caspase1 activation and processing of&#xD;
      interleukin (IL)-1beta and IL-18 . IL-1b is a major proinflammatory cytokine which induces&#xD;
      IL-6, whereas IL-18 is an inducer of interferon gamma (IFNg) production by Th-1 lymphocytes.&#xD;
      A blood IL-1/IL-6 signature can be defined by increased neutrophilia and CRP concentrations,&#xD;
      whereas an IL-18/IFNg signature is characterized by severe hyperferritinemia, consumptive&#xD;
      coagulopathy and cytopenia. A majority of patients with COVID-19 infections seems to have an&#xD;
      IL-1/IL-6 signature, evolving in the more severe forms toward an IL-18/IFNg signature,&#xD;
      mimicking cytokine profiles observed in other inflammatory diseases such as Still's disease&#xD;
      or hemophagocytic syndromes. In Still's disease, therapeutic inhibition of IL-1 or IL-6 has&#xD;
      proven to be very efficient strategies. During hemophagocytic syndromes, inhibition of IFNg&#xD;
      is effective in humans notably through blockade of its receptor signalization, using the JAK&#xD;
      kinase inhibitor ruxolitinib.&#xD;
&#xD;
      Following this strategy, we propose to use biological drugs currently available for&#xD;
      inhibition of IL-1 (anakinra), IL-6 (tocilizumab) or IFNg signaling (ruxolitinib) in the&#xD;
      severe forms of COVID19-associated disease. Our hypothesis is that IL-1, IL-6 or JAK kinase&#xD;
      inhibition will allow:&#xD;
&#xD;
        1. to prevent stage 2b worsening and the need to be admitted in ICU, by decreasing&#xD;
           oxygen-requirement and systemic inflammation&#xD;
&#xD;
        2. to improve stage 3 and extremely severe stage 3, allowing invasive mechanical&#xD;
           ventilation weaning, improving multi-system organ dysfunction, leading to a faster ICU&#xD;
           exit.&#xD;
&#xD;
      We propose an open randomized therapeutic trial (1/1/1) on 216 patients with severe stage 2b&#xD;
      and 3 of the disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilation free days at D28</measure>
    <time_frame>28 days</time_frame>
    <description>number of days living without mechanical ventilation at D28</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Anakinra +/- Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra +/- Ruxolitinib&#xD;
According to clinical stage (gradual strategy):&#xD;
Stage 2b or 3 : Anakinra +/- ruxolitinib depending of evolution; Advanced stage 3 : Anakinra and Ruxolitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab +/- Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tocilizumab +/- Ruxolitinib&#xD;
According to clinical stage (gradual strategy):&#xD;
Stage 2b or 3 : Tocilizumab +/- ruxolitinib depending of evolution; Advanced stage 3: Tocilizumab +ruxolitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with drugs or procedures in routine clinical practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra +/- Ruxolitinib (stages 2b/3)</intervention_name>
    <description>administration of Anakinra +/- ruxolitinib, depending of evolution</description>
    <arm_group_label>Anakinra +/- Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra and Ruxolitinib (Advanced stage 3)</intervention_name>
    <description>administration of Anakinra and ruxolitinib</description>
    <arm_group_label>Anakinra +/- Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab +/- ruxolitinib (stages 2b/3)</intervention_name>
    <description>administration of Tocilizumab +/- ruxolitinib, depending of evolution</description>
    <arm_group_label>Tocilizumab +/- Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab and Ruxolitinib (Advanced stage 3)</intervention_name>
    <description>administration of Tocilizumab and Ruxolitinib</description>
    <arm_group_label>Tocilizumab +/- Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Treatment with drugs or procedures in routine clinical practice</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 year up to 75 year-old maximum&#xD;
&#xD;
          -  Eligible for resuscitation care in UCI&#xD;
&#xD;
          -  with proven infection with COVID-19, using at least one positive pharyngeal polymerase&#xD;
             chain reaction (PCR) test&#xD;
&#xD;
          -  COVID19 infection pneumonia at&#xD;
&#xD;
               -  Stage 2b: Hypoxemic pneumonia (respiratory rate &gt;30/min, Sat O2&lt;90 mm Hg in&#xD;
                  ambient air) associated with a marked biological inflammatory syndrome&#xD;
                  (CRP&gt;150mg/l) - or Stage 3: ARDS defined by a mechanically ventilated patient&#xD;
                  with a PaO2/FiO2 ratio &lt; 300 for more than 24 hours.&#xD;
&#xD;
               -  or Advanced Stage 3: moderate to severe ARDS (PaO2/FiO2 &lt; 200 to PEEP of at least&#xD;
                  8 cmH2O) on invasive mechanical ventilation associated with another organ failure&#xD;
                  or syndrome among : 1) Shock with norepinephrine dosage &gt; 3 mg/hour, 2) Acute&#xD;
                  renal oligo-anuric failure or requiring extra-renal lavage, 3) Hepatocellular&#xD;
                  failure or coagulopathy with factor V &lt; 50%, 4) Myocarditis causing acute heart&#xD;
                  failure and/or shock. , 5) Hemophagocytic syndrome, 6) Hyperferritinemia &gt; 5000&#xD;
                  ng/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 or older than 75 year-old,&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patient for whom measures of therapeutic limitations have been issued (non-admission&#xD;
             to intensive care unit)&#xD;
&#xD;
          -  Patients treated with immunosuppressant/immunomodulators (Not only the concomitant&#xD;
             administration of the following drugs prohibited in the protocol: other JAK&#xD;
             inhibitors, corticosteroids, IL6 inhibitors).&#xD;
&#xD;
          -  Patient already included in another interventional therapeutic trial&#xD;
&#xD;
          -  Use of chronic oral corticosteroids &gt; 10 mg prednisone equivalent per day for&#xD;
             non-COVID-19 related disease&#xD;
&#xD;
          -  Uncontrolled autoimmune disease&#xD;
&#xD;
          -  Patients with active, suspected or known active systemic bacterial, viral (excluding&#xD;
             COVID-19) or fungal infections that are not controlled (not only HIV, HBV or HCV&#xD;
             infection and untreated bacterial or mycotic infection)&#xD;
&#xD;
          -  Patients with severe pre-existing uncontrolled organ dysfunction (heart, liver or&#xD;
             kidney failure) not related to COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gilles Kaplanski, MD</last_name>
    <email>gilles.kaplanski@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique HÃ´pitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gilles Kaplanski</last_name>
      <email>gilles.kaplanski@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

